Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record.

Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia

Open access
Lønborg, Jacob, Kelbæk, Henning, Vejlstrup, Niels, Bøtker, Hans Erik, Kim, Won Yong, Holmvang, Lene, Jørgensen, Erik, Helqvist, Steffen, Saunamäki, Kari, Terkelsen, Christian Juhl, Schoos, Mikkel Malby, Køber, Lars, Clemmensen, Peter, Treiman, Marek, Engstrøm, Thomas · 2012 · Circulation: Cardiovascular Interventions

Abstract

Background—: Exenatide has been demonstrated to be cardioprotective as an adjunct to primary percutaneous coronary intervention in patients with ST-segment–elevation myocardial infarction (STEMI). The aim of the post hoc analysis study was to evaluate the effect of exenatide in relation to system delay, defined as time from first medical contact to first balloon. Methods and Results—: Patients with STEMI and Thrombolysis In Myocardial Infarction flow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion. Study treatment was commenced 15 minutes before intervention and maintained for 6 hours after the procedure. The patients were stratified according to median system delay (132 minutes). Final infarct size and myocardial area at risk were measured by cardiovascular magnetic resonance. Among patients with a system delay ≤132 minutes (n=74), treatment with exenatide resulted in a smaller infarct size (9 grams [interquartile range (IQR), 4–13] versus 13 grams [IQR, 8–24], P =0.008, corresponding to 8% [IQR, 4–12] versus 11% [IQR, 7–17] of the left ventricle, P =0.015). In a regression analysis adjusting for myocardial area at risk the data points of the exenatide group lay significantly lower than for the placebo group ( P =0.006). In the patients with system delay >132 minutes (n=74) no difference was observed in infarct size expressed as grams ( P =0.49) or percentage ( P =0.46). There was significant interaction between system delay (less than or equal to median versus greater than median) and treatment allocation in terms of infarct size ( P =0.018). Conclusions—: In this post hoc analysis, exenatide treatment was associated with a 30% decrease in final infarct size in patients with short system delay, whereas no cardioprotective effect in patients with long system delay was seen. However, this finding must be confirmed in larger studies. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00835848.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circinterventions.112.968388

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 210

Metadata

Authors
Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H. E., Kim, W. Y., Holmvang, L., Jørgensen, E., Helqvist, S., Saunamäki, K., Terkelsen, C. J., Schoos, M. M., Køber, L., Clemmensen, P., Treiman, M., & Engstrøm, T.
Venue
Circulation: Cardiovascular Interventions
Published
2012-04
Volume
5
Issue
2
Pages
288-295
ISSN
  • 1941-7632 (ISSN-L)
  • 1941-7640
OpenAlex
W1980022623
Cited by
210
References
0
FWCI
16.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia. https://app.cochat.ai/papers/10.1161/circinterventions.112.968388
The paper
Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H. E., Kim, W. Y., Holmvang, L., Jørgensen, E., Helqvist, S., Saunamäki, K., Terkelsen, C. J., Schoos, M. M., Køber, L., Clemmensen, P., Treiman, M., & Engstrøm, T. (2012). Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.112.968388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.